GenFleet's Oral KRAS G12D Inhibitor GFH375/VS‑7375 Delivers Positive Data Across Global Studies – World's First KRAS G12D Agent in Phase III for NSCLC and Pancreatic Cancer
CompanyDrug

GenFleet’s Oral KRAS G12D Inhibitor GFH375/VS‑7375 Delivers Positive Data Across Global Studies – World’s First KRAS G12D Agent in Phase III for NSCLC and Pancreatic Cancer

GenFleet Therapeutics (HKG: 2595) announced, in a voluntary disclosure, positive progress in the clinical development of GFH375/VS‑7375, its orally active, highly selective small‑molecule KRAS G12D inhibitor, with latest data from…

Centergate Technologies Subsidiary Duoduo Pharmaceutical Has Calcium Dobesilate Capsules Application Accepted by NMPA – Generic Filing Enters Review for Established Capillary Protectant
CompanyDrug

Centergate Technologies Subsidiary Duoduo Pharmaceutical Has Calcium Dobesilate Capsules Application Accepted by NMPA – Generic Filing Enters Review for Established Capillary Protectant

Tasly Pharmaceutical Receives NMPA Clinical Trial Approval for TDX105 Granules – Category 1.1 TCM Innovative Drug Targeting Chemotherapy‑Induced Hand‑Foot Skin Reactions
CompanyDrug

Tasly Pharmaceutical Receives NMPA Clinical Trial Approval for TDX105 Granules – Category 1.1 TCM Innovative Drug Targeting Chemotherapy‑Induced Hand‑Foot Skin Reactions

Sino Biopharmaceutical's Hepatitis B Assets Take Center Stage at AASLD 2026 – Bepirovirsen Phase 3 Functional Cure Data and TQ‑A3334 Late‑Breaking Phase II Results Slated for Oral Presentation
CompanyDrug

Sino Biopharmaceutical’s Hepatitis B Assets Take Center Stage at AASLD 2026 – Bepirovirsen Phase 3 Functional Cure Data and TQ‑A3334 Late‑Breaking Phase II Results Slated for Oral Presentation

Vir Biotechnology and Gilead Strike Collaboration to Engineer Three PRO‑XTEN Dual‑Masked T‑Cell Engagers – Deal Worth Up to USD 1.88 Billion in Milestones
CompanyDeals

Vir Biotechnology and Gilead Strike Collaboration to Engineer Three PRO‑XTEN Dual‑Masked T‑Cell Engagers – Deal Worth Up to USD 1.88 Billion in Milestones

- Advertisement -
Ad image
CompanyDrug

Sino Biopharmaceutical’s TRD205 Secures NMPA Breakthrough Therapy Designation for Chronic Post-Surgical Neuropathic Pain

Insilico Medicine and Bora Pharmaceuticals Forge $2.5B Strategic Alliance to Pioneer AI-Driven Drug R&D
CompanyDeals

Insilico Medicine and Bora Pharmaceuticals Forge $2.5B Strategic Alliance to Pioneer AI-Driven Drug R&D

CompanyDrug

Lynk Pharmaceuticals Completes Phase 3 Enrollment for Zemprocitinib in Ankylosing Spondylitis Trial

CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem
CompanyDeals

CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem

Policy / Regulatory

China’s State Council Unveils “15th Five-Year” National Health Plan with Strong Support for Innovative Therapeutics and AI Integration

CompanyDrug

Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases

Policy / Regulatory

China’s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines

CompanyDrug

B&K Corporation Completes Patient Enrollment in Phase II Diabetic Foot Ulcer Trial for Pro-101-2 rhPDGF-BB Therapy

CompanyDrug

Huadong Medicine’s Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment

CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Clinical Trial Approval for SHR-3079 in Systemic Lupus Erythematosus and Rheumatoid Arthritis

CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer

CompanyDeals

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

Show More